News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
619,621 Results
Type
Article (49362)
Company Profile (398)
Press Release (569861)
Section
Business (161756)
Career Advice (3082)
Deals (29829)
Drug Delivery (109)
Drug Development (80173)
Employer Resources (174)
FDA (15142)
Job Trends (13102)
News (292401)
Policy (28650)
Tag
Academia (2726)
Alliances (43301)
Alzheimer's disease (1374)
Approvals (15103)
Artificial intelligence (218)
Bankruptcy (286)
Best Places to Work (10879)
Biotechnology (305)
Breast cancer (240)
Cancer (1841)
Cardiovascular disease (146)
Career advice (2593)
CAR-T (147)
Cell therapy (419)
Clinical research (64413)
Collaboration (709)
Compensation (358)
COVID-19 (2525)
C-suite (176)
Data (1705)
Diabetes (232)
Diagnostics (5543)
Earnings (60052)
Employer resources (152)
Events (105267)
Executive appointments (555)
FDA (16081)
Funding (629)
Gene therapy (296)
GLP-1 (737)
Government (4300)
Healthcare (18163)
Infectious disease (2631)
Inflammatory bowel disease (135)
Interviews (601)
IPO (14442)
Job creations (2704)
Job search strategy (2130)
Layoffs (414)
Legal (5928)
Lung cancer (264)
Manufacturing (255)
Medical device (11613)
Medtech (11616)
Mergers & acquisitions (15817)
Metabolic disorders (640)
Neuroscience (1822)
NextGen: Class of 2025 (6250)
Non-profit (4485)
Northern California (2109)
Obesity (361)
Opinion (255)
Patents (173)
People (47524)
Phase I (20258)
Phase II (28513)
Phase III (21168)
Pipeline (788)
Postmarket research (2387)
Preclinical (8556)
Radiopharmaceuticals (261)
Rare diseases (367)
Real estate (4912)
Regulatory (20240)
Research institute (2407)
Resumes & cover letters (493)
Southern California (1811)
Startups (3226)
United States (18653)
Vaccines (605)
Weight loss (270)
Date
Today (71)
Last 7 days (787)
Last 30 days (2649)
Last 365 days (34071)
2025 (5296)
2024 (34854)
2023 (38957)
2022 (49045)
2021 (53222)
2020 (50940)
2019 (43879)
2018 (33189)
2017 (30704)
2016 (30197)
2015 (34732)
2014 (27078)
2013 (22138)
2012 (23189)
2011 (23752)
2010 (21738)
Location
Africa (844)
Arizona (154)
Asia (36428)
Australia (6464)
California (4829)
Canada (1673)
China (416)
Colorado (216)
Connecticut (226)
Europe (84999)
Florida (691)
Georgia (164)
Illinois (465)
Indiana (253)
Maryland (717)
Massachusetts (3847)
Michigan (193)
Minnesota (309)
New Jersey (1363)
New York (1376)
North Carolina (878)
Northern California (2109)
Ohio (169)
Pennsylvania (1093)
South America (1126)
Southern California (1811)
Texas (690)
Utah (133)
Washington State (482)
619,621 Results for "the obesity society".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments
Obesity drug developers Aardvark, Helicore and Metsera have all netted raises in the past two weeks.
February 13, 2025
·
1 min read
·
Dan Samorodnitsky
Obesity
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by
The Lancet Diabetes & Endocrinology
—indicate an evolving mindset toward treating obesity as a chronic disease.
March 3, 2025
·
7 min read
·
Kate Goodwin
Weight loss
FDA Proposes Draft Guidance for Weight-Loss Therapies as Obesity Space Heats Up
The FDA recommended maintaining a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of their investigational obesity candidates.
January 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Ro selected to present new research at The Obesity Society’s ObesityWeek 2024
November 5, 2024
·
7 min read
Business
2025 Investment to Swing Toward I&I, Obesity, More: Experts
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune diseases, a continued appetite for next-generation obesity drugs and an increased focus on neuromuscular, kidney and cardiovascular diseases.
January 21, 2025
·
7 min read
·
Heather McKenzie
Obesity
Obesity-Focused Aardvark Therapeutics Files IPO to Advance Lead Candidate
The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.
January 24, 2025
·
1 min read
·
Dan Samorodnitsky
GLP-1
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera Therapeutics outlining their plans in the space moving forward.
January 14, 2025
·
2 min read
·
Tristan Manalac
Startups
Versant Launches Fourth Obesity Startup Helicore to Improve Weight Loss Quality
Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 million and a GIP-targeting asset intended to induce higher-quality weight loss.
January 28, 2025
·
2 min read
·
Tristan Manalac
Podcast
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees more action with new company launches, IPOs and fresh data; and experts get ready for an important era in the Duchenne muscular dystrophy space.
January 29, 2025
·
1 min read
·
Heather McKenzie
Obesity
BioAge Crashes After Axing Phase II Obesity Study
The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen announced underwhelming mid-stage data for MariTide.
December 9, 2024
·
2 min read
·
Tristan Manalac
1 of 61,963
Next
